The NRG Oncology/NSABP B-51/RTOG 1304 clinical trial, results of which were presented at the 2023 San Antonio Breast Cancer Symposium (Abstract GS02-07), examined potential treatment de-escalation options in patients whose breast cancer converted from lymph node–positive to –negative following treatment.
